Clinical Trial Update: Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) [Phase 2]

View source ↗

Summary

Phase 2, multi-center trial evaluating the combination of lenalidomide (Revlimid) and rituximab as first-line therapy for chronic lymphocytic leukemia; the stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Revlimid (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: Chronic Lymphocytic Leukemia Research Consortium | Conditions: Chronic Lymphocytic Leukemia, CLL | Phase 2 | Status: UNKNOWN